2.37
price up icon7.73%   0.17
after-market After Hours: 2.38 0.010 +0.42%
loading
Nkarta Inc stock is traded at $2.37, with a volume of 1.88M. It is up +7.73% in the last 24 hours and down -5.20% over the past month. Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
See More
Previous Close:
$2.20
Open:
$2.18
24h Volume:
1.88M
Relative Volume:
1.50
Market Cap:
$167.25M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.9258
EPS:
-2.56
Net Cash Flow:
$-114.31M
1W Performance:
+1.28%
1M Performance:
-5.20%
6M Performance:
-55.24%
1Y Performance:
-35.42%
1-Day Range:
Value
$2.15
$2.405
1-Week Range:
Value
$2.08
$2.50
52-Week Range:
Value
$2.08
$16.24

Nkarta Inc Stock (NKTX) Company Profile

Name
Name
Nkarta Inc
Name
Phone
(925) 407-1049
Name
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Name
Employee
159
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
NKTX's Discussions on Twitter

Compare NKTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NKTX
Nkarta Inc
2.37 167.25M 0 -117.50M -114.31M -2.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Nkarta Inc Stock (NKTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-09-24 Initiated Rodman & Renshaw Buy
Aug-14-24 Upgrade Raymond James Outperform → Strong Buy
Mar-22-24 Downgrade Raymond James Strong Buy → Outperform
Dec-22-22 Downgrade Oppenheimer Outperform → Perform
Oct-10-22 Initiated Canaccord Genuity Buy
Jul-28-22 Initiated Needham Buy
Jul-18-22 Initiated SVB Leerink Outperform
Mar-11-22 Initiated Raymond James Outperform
Mar-08-22 Initiated H.C. Wainwright Buy
Jan-06-22 Initiated William Blair Outperform
Nov-18-21 Initiated SMBC Nikko Outperform
Jul-16-21 Initiated Oppenheimer Outperform
Aug-04-20 Initiated Cowen Outperform
Aug-04-20 Initiated Evercore ISI Outperform
Aug-04-20 Initiated Mizuho Buy
Aug-04-20 Initiated Stifel Buy
View All

Nkarta Inc Stock (NKTX) Latest News

pulisher
Dec 19, 2024

Fmr LLC Has $602,000 Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Dec 19, 2024
pulisher
Dec 17, 2024

Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase By Investing.com - Investing.com Australia

Dec 17, 2024
pulisher
Dec 17, 2024

Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase - Investing.com India

Dec 17, 2024
pulisher
Dec 13, 2024

Citadel Advisors LLC's Strategic Acquisition of Nkarta Inc Shares - GuruFocus.com

Dec 13, 2024
pulisher
Dec 10, 2024

Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment By Investing.com - Investing.com South Africa

Dec 10, 2024
pulisher
Dec 09, 2024

Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment - Investing.com UK

Dec 09, 2024
pulisher
Dec 06, 2024

Major Improvements In Nkarta Inc (NKTX) Stock Need To Be Considered - Stocks Register

Dec 06, 2024
pulisher
Dec 05, 2024

Nkarta’s Ntrust-2 trial of NKX019 in myasthenia gravis begins enrollment - TipRanks

Dec 05, 2024
pulisher
Dec 05, 2024

Nkarta Announces IND Clearance of Investigator-Sponsored - GlobeNewswire

Dec 05, 2024
pulisher
Dec 05, 2024

Nkarta Expands NKX019 Cell Therapy Trial to 4 New Autoimmune Diseases, Breakthrough Treatment Protocol Unveiled - StockTitan

Dec 05, 2024
pulisher
Dec 01, 2024

Wasatch Advisors LP Has $8.29 Million Stake in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Nkarta, Inc. (NASDAQ:NKTX) Sees Large Drop in Short Interest - MarketBeat

Nov 30, 2024
pulisher
Nov 28, 2024

Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World

Nov 28, 2024
pulisher
Nov 28, 2024

Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Analysts - Defense World

Nov 28, 2024
pulisher
Nov 28, 2024

Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Buy" by Brokerages - MarketBeat

Nov 28, 2024
pulisher
Nov 28, 2024

Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Brokerages - MarketBeat

Nov 28, 2024
pulisher
Nov 26, 2024

Nkarta to Participate in an Upcoming Investor Conference - GlobeNewswire

Nov 26, 2024
pulisher
Nov 26, 2024

Nkarta to Present NK Cell Therapy Advances at Evercore HealthCONx Conference | NKTX Stock News - StockTitan

Nov 26, 2024
pulisher
Nov 22, 2024

Nkarta price target lowered to $16 from $20 at Mizuho - Yahoo Finance

Nov 22, 2024
pulisher
Nov 21, 2024

Mizuho Lowers Nkarta (NASDAQ:NKTX) Price Target to $16.00 - MarketBeat

Nov 21, 2024
pulisher
Nov 19, 2024

NKTX stock touches 52-week low at $2.44 amid market fluctuations - Investing.com

Nov 19, 2024
pulisher
Nov 15, 2024

COMMODORE CAPITAL LP Acquires Shares in Nkarta Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Despite Hitting US$2.91, Nkarta Insiders Still Sold Too Soon - Simply Wall St

Nov 14, 2024
pulisher
Nov 12, 2024

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace

Nov 12, 2024
pulisher
Nov 12, 2024

Nkarta to Present at Stifel Healthcare Conference: NK Cell Therapy Updates Expected | NKTX Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Nkarta (NASDAQ:NKTX) Price Target Cut to $18.00 by Analysts at HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 08, 2024

Nkarta (NASDAQ:NKTX) Given New $11.00 Price Target at Needham & Company LLC - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Nkarta, Inc. Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewswire

Nov 07, 2024
pulisher
Nov 06, 2024

Nkarta, Inc. (NASDAQ:NKTX) Receives $17.50 Average PT from Brokerages - Defense World

Nov 06, 2024
pulisher
Nov 03, 2024

Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Price Target at $17.50 - MarketBeat

Nov 03, 2024
pulisher
Oct 31, 2024

Nkarta (NKTX) Stock: Looking For Upside - Seeking Alpha

Oct 31, 2024
pulisher
Oct 30, 2024

Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade) - Seeking Alpha

Oct 30, 2024
pulisher
Oct 29, 2024

SG Americas Securities LLC Purchases New Shares in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Oct 29, 2024
pulisher
Oct 25, 2024

Bleakley Financial Group LLC Has $69,000 Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Oct 25, 2024
pulisher
Oct 18, 2024

Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

GAMMA Investing LLC Increases Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Oct 18, 2024
pulisher
Oct 15, 2024

Are Nkarta Inc (NKTX) shares a good deal now? - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Daily Market Movement: Nkarta Inc (NKTX) Sees a 1.29 Increase, Closing at 3.94 - The Dwinnex

Oct 15, 2024
pulisher
Oct 14, 2024

Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Dimensional Fund Advisors LP - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

AQR Capital Management LLC Invests $938,000 in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat

Oct 13, 2024
pulisher
Oct 11, 2024

Nkarta Inc (NKTX) Stock: A Year of Market Fluctuations - The InvestChronicle

Oct 11, 2024
pulisher
Oct 10, 2024

Nkarta (NASDAQ:NKTX) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World

Oct 10, 2024
pulisher
Oct 10, 2024

Nkarta (NASDAQ:NKTX) Upgraded to "Strong-Buy" by RODMAN&RENSHAW - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Nkarta, Inc. (NASDAQ:NKTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Nkarta (NASDAQ:NKTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Raymond James upgrades Nkarta Inc (NKTX) stock to a Strong buy - Knox Daily

Oct 09, 2024
pulisher
Oct 08, 2024

Nkarta upgraded at Raymond James on valuation - MSN

Oct 08, 2024

Nkarta Inc Stock (NKTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Nkarta Inc Stock (NKTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Trager James
Chief Scientific Officer
Jun 18 '24
Sale
5.60
456
2,554
150,959
HASTINGS PAUL J
Chief Executive Officer
Jun 18 '24
Sale
5.60
1,770
9,912
240,737
Shook David
Chief Medical Officer
Jun 18 '24
Sale
5.60
456
2,554
116,524
Hager Alicia J.
Chief Legal Officer
Jun 18 '24
Sale
5.60
727
4,071
107,215
Brandenberger Ralph
Chief Technical Officer
Jun 18 '24
Sale
5.60
229
1,282
79,743
RA CAPITAL MANAGEMENT, L.P.
Director
Mar 27 '24
Buy
10.00
3,000,000
30,000,000
10,050,818
George Simeon
Director
Mar 27 '24
Buy
10.00
2,000,000
20,000,000
1,548,341
Brandenberger Ralph
Chief Technical Officer
Mar 01 '24
Option Exercise
3.89
6,763
26,308
88,339
Brandenberger Ralph
Chief Technical Officer
Mar 01 '24
Sale
12.51
8,367
104,671
79,972
Trager James
Chief Scientific Officer
Feb 12 '24
Sale
12.00
4,143
49,716
149,415
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Cap:     |  Volume (24h):